Herpes Blocker® Valcyclovir (500 mg tablets), Oral
The herpes virus affects at least one out of 4 people! This antiviral medicine taken according to Vie’s protocol reduces outbreaks and prevents transmission. Stopping transmission means to not only prevent giving the virus to someone but also to protect you from catching it.
- reduces breakouts
- shown to reduce transmission (giving or receiving)
- take at least 30 minutes before sex
- 1 year protocol available to neutralize virus long-term!
500 mg tablet
We Also Recommend for You
Sildenafil + The Love Hormone® Oxytocin and Sexy Gum®, Oral$60.00 Select options
Tadalafil + The Love Hormone® Oxytocin, Oral$60.00 Select options
More Please® Multiorgasm Pill Cabergoline, Oral$96.00 Select options
The Pleasure Pill® Apomorphine (15 Troches), Oral$60.00 Add to cart
Screem Creem® (30 grams = 30 cc)$50.00 Select options
Malibu Pill® Melanotan I Injectable/Nasal Spray (5 ml = at least 50 doses)$220.00 Read more
PT-141 (10,000 mcg/ml), Injectable$240.00 Add to cart
Pink Again® Anal Bleach, Topical$66.00 Select options
Period Blocker®, Oral$90.00 Select options
The Love Hormone® – Oxytocin intranasal (5 ml = 50 sprays)$75.00 Add to cart
Make Me Wet® Estrogen (5 mg estradiol) Vaginal dissolving troche (24 doses)$50.00 Select options
notes: This medicine is used to block the spread (giving or receiving) of the Herpes virus or to give long-term suppression. Clinical studies of Herpes (skin to skin contact herpes ) can be prevented. Because of ethical concerns, similar studies can not be done on genital herpes, but the virus’ are similar. Also, longer term treatment with anti-viral medicine has consistently been shown to induce remission and often non-detection of the virus.
The prescription from Vie has both the preventive protocol and long-term suppression protocols.
Clin J Sport Med. 2016 Jul;26(4):272-8. doi: 10.1097/JSM.0000000000000255.
Prophylactic Valacyclovir to Prevent Outbreaks of Primary Herpes Gladiatorum at a 28-Day Wrestling Camp: A 10-Year Review.
Anderson BJ1, McGuire DP, Reed M, Foster M, Ortiz D.
To determine efficacy of using oral antiviral medication to reduce herpes gladiatorum (HG) at summer high-school wrestling camps.
Usage of antiviral medication hypothetically reduces the likelihood of HG outbreaks. This is an observational study examining the effectiveness of oral antiviral medications in reducing outbreaks of HG because of Herpes Simplex type-1 virus (HSV).
A 28-day high-school summer wrestling camp at the University of Minnesota from 2003 to 2012.
Each summer approximately 300 high-school wrestlers, age 13 to 18 years of age, participated in this camp.
All athletes were recommended to take valacyclovir 1 g once a day for the duration of the camp. Athletes who did not use any antiviral medication
comprised the comparison group for this study. Individuals were screened daily and those with outbreaks of HG were withheld from practice for 120 hours in accordance with National Collegiate Athletic Association/National Federation of State High School Associations guidelines.
MAIN OUTCOME MEASURES:
To measure viral outbreaks of HG due to HSV-1, determine level of compliance, and determine efficacy of antiviral medication in reducing the occurrence of HG at this 28-day wrestling camp.
Of the 2793 athletes who completed camp, 1995 (71%) used antiviral medication, and 36 outbreaks occurred. Eighty-four athletes had a known history of HG/recurrent herpes labialis. Overall, prophylactic antiviral medication resulted in an 84.7% decrease in the probability of an outbreak. Prophylactic valacyclovir (1 g daily) lowered the incidence of individual outbreaks by 89.5%.
Prophylactic use of valacyclovir 1 g once a day is efficacious in lowering the incidence of HSV outbreaks among adolescents at a 28-day wrestling camp.
Clin J Sport Med. 1999 Apr;9(2):86-90.
The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers.
To determine whether nucleoside analogues can suppress recurrent outbreaks of herpes simplex virus type 1 (HSV-1) in wrestlers, commonly called herpes gladiatorum.
Double-blind and open study using valacyclovir over two wrestling seasons from 1996 through 1998.
Wrestling community in the Minneapolis-St. Paul area of Minnesota.
Volunteer sample of 42 male wrestlers from 13 to 31 years of age. For inclusion, patients had to have recurrent herpes gladiatorum and be active in a wrestling program.
Participants were treated during the first half of the season in a double-blind study using valacyclovir 500 mg a day, and in the second half as an open study with all wrestlers using valacyclovir 1,000 mg.
MAIN OUTCOME MEASURES:
Outbreak of herpes gladiatorum based on clinical appearance or culture.
Participants were divided into two groups based on time interval since primary outbreak of herpes gladiatorum: less than 2 years or more than 2 years. For patients in whom primary outbreak was less than 2 years ago, outbreaks occurred in 21% (3/14) of those receiving valacyclovir 500 mg per day and 8% (2/25) of those receiving valacyclovir 1,000 mg per day. For patients in whom primary outbreak was more than 2 years ago, outbreaks occurred in 0% (0/7) of those receiving valacyclovir 500 mg per day and 0% (0/12) of those receiving valacyclovir 1,000 mg per day.
For patients with a history of herpes gladiatorum of more than 2 years, valacyclovir 500 mg daily suppresses recurrent outbreaks. Further studies need to be performed to determine proper dosing regimen for suppression of outbreaks in patients with a disease duration of less than 2 years.